University of Paris-Sorbonne-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2023

  1. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 6, pp. 754-762

  2. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

    RMD Open, Vol. 9, Núm. 1

  3. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

    RMD Open, Vol. 9, Núm. 1

2022

  1. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

    Annals of the rheumatic diseases, Vol. 81, Núm. 1, pp. 34-40